Glaukos (GKOS) Stock Soars After Blowout Q3 Earnings Beat
Glaukos (GKOS) stock surged 33.65% after Q3 earnings beat expectations, reporting EPS of $0.47 vs. -$0.09 and revenue of $211M vs. $168.1M. The company raised FY26 and FY27 revenue guidance, citing strong performance of iDose TR and Epioxa. Analysts upgraded price targets, with BTIG at $205 and Mizuho at $190.
How this was made
The 30-second read
Why it matters
Traders are likely to treat this as a valuation reset event: the earnings beat and raised FY26-FY27 revenue targets can change forward expectations, while Phase 4 and Phase 3 extension data reduce perceived clinical risk for iDose TR and Epioxa.
Market read
A same-company earnings beat plus explicit FY26 and FY27 revenue guidance raises the bar for future growth, making GKOS a near-term momentum and rerating candidate.
What to watch
Sustaining demand and reimbursement for iDose TR and Epioxa, plus any post-run volatility around follow-on clinical/regulatory milestones, could determine whether the rerating holds beyond the initial momentum window.
Background
The piece frames Glaukos as a high-growth, historically low-profitability ophthalmology platform that has now delivered an earnings and guidance reset alongside supportive clinical updates.
Ticker impact
Glaukos reported a Q3 EPS beat ($0.47 vs -$0.09) and revenue beat (~$211M vs $168.1M), then guided FY26-FY27 higher.
Likely further upside pressure as traders extend the earnings-gap momentum and reprice growth expectations toward the new FY27 revenue path.
The article provides same-quarter beat magnitudes, explicit FY26 and FY27 revenue guidance ranges, and additional clinical-data reinforcement, all of which are direct drivers of near-term valuation and positioning.
Market effects
Positive read-through for glaucoma and corneal/retinal medtech sentiment, reinforcing risk-on appetite for clinical-stage commercial franchises with improving profitability.
Primarily US small/mid-cap biotech and medtech momentum, with potential spillover into healthcare growth factors.
Limited direct global macro linkage; impact is mostly company-specific within ophthalmology/medtech.
Counterpoint
The move may be vulnerable to profit-taking because the article notes negative historical margins and heavy expectations embedded in the FY27 $1.0B target.
Key entities
- companyGlaukos Corporation
Subject of the article, NYSE-listed GKOS, with Q3 earnings beat, raised revenue guidance, and supportive clinical data.
- productiDose TR
Glaukos glaucoma therapy referenced with Phase 4 data supporting additional pressure reduction and a favorable three-month safety profile.
- productEpioxa
Glaukos corneal therapy referenced with three-year Phase 3 extension data showing durable improvements and no repeat treatment need.
- commercial_agreementRevOpsis deal
Exclusive rights to RO-104 and the RevMod platform for up to four new retinal biologics, expanding the retinal pipeline.
